Phytochemical investigation identifies potent enzyme inhibitors in Camellia kissi leaves, suggesting potential therapeutic uses.
One new phenolic glycoside, eugenyl O-β-D-allopyranoside (1), along with 11 known compounds, including sasanquin (2), vomifoliol (3), (6 R,9S)-3-O-oxo-α-ionol β-D-glucopyranoside (4), (+)-lyoniresinol 4-O-β-D-glucopyranoside (5), nudiposide (6), icariside E4 (7), dihydrodehydrodiconiferyl alcohol (8), 3β-hydroxy-olean-11,13(18)-dien-28-oic acid (9), oleanolic acid (10), 3,4,3′-tri-O-methylellaic acid (11), and kaempferol 3-O-α-L-rhamnopyranoside (12) were isolated from the leaves of Camellia kissi Wall. All compounds were evaluated for inhibitory activities against acetylcholinesterase, α-glucosidase, and nitric oxide production. As a result, compound 1 showed a significant inhibitory effect on acetylcholinesterase with an IC50 value of 10.09 ± 0.61 µM. Compounds 9 and 10 showed significant inhibitory α-glucosidase activity with an IC50 value of 17.62 ± 1.32 and 33.99 ± 1.97 µM, respectively. Compounds 2 and 9 showed significant nitric oxide inhibitory activity with IC50 values of 19.87 ± 1.09 and 16.74 ± 0.66 µM, respectively. These results represent the first phytochemical investigation and biological screening of constituents from C.kissi.
No takes yet. Share an insight, caveat, or question.
Ha et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: